today's us Thank you, you appreciate Jennifer, joining We and afternoon, update. everyone. for good
on issued Thrombotic As from Microangiopathy you Transplant-Associated we Cell pivotal saw, or Cell our likely release Stem a TMA. the in Stem narsoplimab data trial Hematopoietic today press
historically of inventories December year-end at at increase over a compared million, consistent summary quarter This a I'll OMIDRIA call XX, with XX% to wholesaler held that the of Net to our wholesalers. were and narsoplimab XXXX, run record. the brief start data. sales highlights XX% of XXXX our those quarter increase a with in important and fourth here another then today's fourth new by immediately $XX.X financial through last quarter. note were our represents It's
into expenses share. costs these also $X.XX Lonza fourth charge These for $XX.X quarter per lots lots as BLA successful and narsoplimab or process XXXX of or satisfy five includes a accelerating of set was approval including due of approval. $X.XX share. all the the or per our loss regulatory million for are This net sale Our quarter under million prior fourth available at million a share commercial of requirements accounting, This to our non-cash FDA's of includes expensed $X.X following three incurred manufacturing the to will manufacture $X.XX lots be one-time per validation lots. of of for $XX.X R&D. GAAP
result, goods As when these there be cost almost no a will are realized sold. of lots
we when one-time burn and the cash lots, of for overall approximately out So the $XX was quarter net non-cash the expenses our million. manufacturer PV
As available of approximately investments operations. had for year-end, million we of $XX and cash general
accounts to $XX have credit, of our baseline million eligible We allows XX% receivable also receivable. of borrow which to accounts up a us
this data release, quarter. our Now, pivotal the patients. that License speak our stem and Application antibody and let's or designated right therapy today's often Enrollment submit generated breakthrough TMA for the with TMA pivotal FDA narsoplimab that possible. for in lethal obtain to the first approval to first trial, last and for enrolled number agreement product our from is for rolling satisfied is the of of treatment objective in cell as were stem summarized BLA submitted as FDA. get is to FDA patients There stopped the MASP-X no to our trial which and data strongly are approval disorder quickly were press sections narsoplimab The to data question. registration pivotal approved the this our sufficient in was the cell from trial Biologics
our data, trial. the who like participated families, jumping to other in into patients, physician I'd the their and investigators Before the caregivers thank
appreciated, and expect are that patients. efforts the improved significantly we sincerely stem together, cell transplant I have lives future Your of
are, one, of and meeting threshold stem TMA Two two, program aspects important endpoint. the primary our cell that the data. Now let's look at definition for endpoint, the the of
clear definition studied. that a Omeros discussed, previously the demonstrates ill to that benefit in meaningful worked FDA of As very we have response we with develop population reviewers
endpoint the of detail the findings. of XX% in severely rigorous graft-versus-host press ill agreed nature XX demonstrates provides the immunosuppression significant which FDA efficacy benefit. complete threshold entry today's described this of the the definition complications to release, As in treatment test a FDA response the patient risk of XX% The and four of population into and patient rate, criterion primary elevated and intent them pulmonary at TMA population were of endpoint agreed expected primary the of of of received of for narsoplimab. our treat poor one patients a were dosing responders. who having risk at their cell received noninfectious outcomes. and a Patients protocol-specified stem TMA had enrolled trial persistence the including least trial patients multiple FDA-agreed disease, weeks in despite factors, XX% in stem response in XX% with complete patients trial; high of itself mortality met of was cell least modification of the and dose infections, neurological
Both to X.XXXX. above confidence of rates XX%. response of FDA is XX% both who to the XX% XX% dosing, and protocol-specified for patients for XX%, interval The those for at threshold In weeks four p-values these is received efficacy. confidence well agreed populations, these the less XX% the to XX% than all are translate interval least
in the -- was and XXX-day in The impressive. across protocol-specified secondary group, patients, survival endpoint XX% XX XX% equally across XX% responders. treatment patients all of
assessments than and Narsoplimab and has baseline LDH Laboratory development endpoints patients, secondary of from platelets well with all statistically also been unchanged significant X.XX p our tolerated across haptoglobin. for less efficacy values meaningful across improvement programs. demonstrate
sepsis, diarrhea, and fever, reported common patients. Six and cell stem trial. transplant patient in adverse the neutropenia to population. in trial, all disease the deaths In disease, causes occurred during These progression this of were nausea, due stem common the TMA events were again, commonly the underlying all death cell hypokalemia, vomiting, of most graft-versus-host
of opinion at trial and Chief transplant Therapy the of with positive. the Director of US and in Similarly, later for opportunity Meeting comprised Board Service European stem Center on premier will the this Stem clinical Orlando, narsoplimab XX Adult a be Marrow Orlando over presented uniformly Marrow in December, upcoming to at transplant Transplant in of Fellowship month. data Deputy clinical Blood US. of Complete the on Feedback in Dr. Annual highly Europe. in Transplantation Perales, American at the Memorial was the some also at leaders discuss data had Transplantation physicians data recent in top trial of Cancer TMA the and Society our Advisory by throughout At from Hematology Society the and education Bone with we Conference, Miguel-Angel cell Cell shared data the Transplantation Meeting an were and the Adult symposium both Sloan-Kettering of the Madrid medical continuing Cellular the and
Chemistry, manufacturing progress inspections for Manufacturing aspects of the near-term that narsoplimab CMC. our At Controls Omeros and discuss release FDA's February data FDA assays to this let's narsoplimab In meeting, year, the for or of the also FDA and met requested with BLA. for Now the agreement CMC on scheduled. discuss on BLA. could dates so requirements be Omeros stability pre-approval reached and FDA
the of accelerate lots Lonza, manufacturing of together a narsoplimab include BLA. completed As timeline. to in we These manufacturing the schedule successful our completed with of required validation were ahead the BLA have partner, process previously to mentioned,
of narsoplimab track. BLA sections remain completed be the the of CMC will on commercial for available of All submission lots our Timing for use.
All Omeros. sections of FDA clinical of CMC quarter. study trial non-clinical the clinical and submitted clinical sections will BLA of The our data remaining clinical The reports last include sections well. to been were at and The the are BLA are in-house and modules. progressing compiled have BLA, rolling already clinical the standard
requested information is patient collected. the collected to connection prior of supply narratives that on historical As was not to such narratives course by including the as with our trial. initially historical the trial, FDA our in breakthrough therapy in out BLA designation, in clinical in the additional detailed These round narratives patients. have already been participation needed clinical the data clinical Most the Omeros
are provided affecting at Omeros and efficacy data in already compiled the in-house all Importantly, endpoints efficacy reflected our and are today. data
the for to at site cause data however, begun. to received. of encountered historical that clinical one has prohibit law the government The administrative delay, collection be on of is That patients delay and deceased slip may until in into collection collection to country any related We of transfer third data requirements an process historical submission or authorization local quarter. early of postmortem the appears issue historical our data administrative the resolved part which
logistics the with in option assessing are submission We earlier. full bring the date several to
TMA narsoplimab Our the also continue launch commercial preparations cell progress. to stem in for of
reviewed on previous is story As calls, value we've behind strong. narsoplimab the
also including from framework stays European a easy narsoplimab profile of Our into number. as response how and and efficacy fit XX-minute admissions, cost treatment and both profile a would complete Feedback them lives and hospital for of settings. represents dovetail reducing transplant and and administrators importance administration infusion payers saving the beyond US stressed care care would unit intensive goes dialysis. inpatient existing current the for their is within treatment paradigms, use outpatient The their
for to ensure we launch be from timed anticipated XXXX, US fully will suffering cell During for out team strategic narsoplimab continue stem prepare our commercial to These to build hires patients milestones will the launch. are ready to that around TMA. we
to narsoplimab. quarter, for Regarding the from by of acceptance EMA's or This CHMP, the Investigation Plan Marketing an our through a Committee EMA a our European opinion adopted we of Pediatric MAA, received for last centralized prerequisite the PIP Authorization EMA's Application opinion Pediatric positive positive MAA was procedure. or
to plan successful eligible MAA. As allow EMA up us after marketing pediatric additional for exclusivity, to until defer will makes approval we two narsoplimab of PIP of of completion the and the noted, of completion the also years
We on and the plan European been the to complete marketing has we for completing filed. BLA the after submission approval are the US currently to submission focused BLA
syndrome, TMA which hemorrhage, initial constellation of others. part graft-versus-host cell injury and of stem veno-occlusive pneumonia include this disease focus, or alveolar While sinusoidal endothelial diffuse a syndromes, obstruction syndrome our disorder idiopathic is disease, is
enzyme activate thought of damage caused which injury narsoplimab be number in MASP-X and known be endothelial so lectin pathway, by syndromes to narsoplimab to the could a to All plan well the effector is are these effective evaluate pathway we lectin them. the of of complement. syndromes endothelial of across is
program Let's our narsoplimab Phase X in turn continues IgA for now to which to progress. nephropathy,
with XX-hour enrolling patients with general subset gram of X our least both proteinuria than levels In the trial, population two from patients ARTEMIS-IGAN and of are grams. the daily of greater proteinuria from at we X Phase
We expect and published The was the research. in world in Inhibition of expected program Barratt nephropathy manuscript Stanford University by comprised Jonathan Leadership "Drugs is in the renal next for nephropathy detailing the of Phase to be Omeros' Also, Nephropathy IgA Academic clinical prepared data from IgA leaders will Committee, the article which Dr. readout soon manuscript is and be University of X a review A IgA published by authored clinical year. Lafayette Potential as Strategy "MASP-X Leicester, journal. journal of a premier entitled peer-reviewed Richard of Future." data Management"
trial Chronic in subcutaneous used Asia enrolling. our uremic is [ph]. AHUS dosing includes multiple is narsoplimab or X of US, sites hemolytic and syndrome the for atypical The in Europe, Phase actively trial and being
previously resources related on IgA noted, narsoplimab are nephropathy, we TMA bulk and expect of cell this after and to TMA our focused both and As complete the stem IgA. program
FDA-approved let's product. Now ophthalmic move our on to OMIDRIA,
training our in then a new quarter for quarter higher facilities. increasing expansion particularly improved existing represent from driven in also the development. evident outcomes continues growth the OMIDRIA OMIDRIA's benefits saw to in continued penetration In OMIDRIA and reintroduction, ASCs, rate ASCs. a is strong, to and were growth demonstrate to first grow hospitals and As across Hospital significant to ASCs. to and to grow This for demand opportunity in only fourth both we results, future encouraging be sales sale accounts Hospitals allow is hospitals they accounts. in sales, fourth us time not these surgeons' an cataract since by
be our of and Medicare the early not important are payers to across two all J-code, when a sites than coverage in new future, of Overall, fourth quarter. and Advantage, of the accounts claims the is of J-code over prior our that across OMIDRIA number of reimbursement results previous C-code would The which commercial reasons. where became payment purchasing standardize a insurance Medicare, Medicaid J-code. new submission and The will we the office in performed. Xst. the under J-code insurance benefited the Fourth reimbursing care. for OMIDRIA's quarter our of under in effective plans. Numerous also OMIDRIA that from J-codes now previously separate providing October cover greater quarter, expanded the cataract for provides the are physician indicate saw also XX% growing procedures This number introduction sales setting important used plans growth
pass-through in second, mandated previous in C-code CMS setting pay independent was of which office one for And is our the OMIDRIA not separately to is First, reimbursed setting. this status.
for to current slated to With is Medicare year. of September CMS Part through and the pass-through, status respect pass on OMIDRIA reimbursement this B XX expire
broad efforts will to continue be to September and payment based remain secure and we We for XX, beyond that pursue legislative we successful. administrative OMIDRIA optimistic
the and also supported organizations strong and Opioid Congressional for X On diverse House alternatives and coalition was fighting and sponsors put by both led the professional Non-Opioids introduced restrict bipartisan in quarter prescribe that other treatment organizations Act referred including the This for Supported grassroots Act management. CMS the to the to and pain House the from currently Senate. nurses Nation Non-Opioid Prevent the XX Choices NOPAIN practitioners Act surgical NOPAIN legislative non-opioid co-sponsors, of and fourth the payment Voices legislation With of gaining designed is the in settings. a is by as common side, NOPAIN remove by by advocacy physicians Addiction is Force, to Representatives Task solutions of ability enjoys in sense the bipartisan groups disincentives Bipartisan to the Senate in in momentum. place Act
status If the seeing, of we steady measurable separate witnessed to legislation columnists, passed, payment progress in as advocates, physicians think have also supporting coverage. Medicare past months, and the legislative anecdotal several would we're the types an And tank third-party provide five a for years. course OMIDRIA complement
such seen Inside makers as and Fierce examples healthcare Morning news as Modern policy as where Business Daily of policy publications are mainstream important we've the Health pieces recent Hill, their as Healio the pro-OMIDRIA well and Investor's and in Times Washington Policy, in Some publications, Healthcare, Healthcare, RealClearHealth. Consult, such The get
to administrative non-opioid by payment mandate to policy. during also Support qualify under under pain would efforts CMS package Congress's are as pay established CMS for for the separately under enables its to CMS response OMIDRIA administered Act. The drugs management that continued We was pursuing exclusion exclusion the non-opioid packaging separate that in surgery drugs non-opioid supplies otherwise
we CMS that opioids that including the exclusion, evidence of associated demonstrating use requested, surgery. OMIDRIA lower after is of squarely continue during As within both evidence OMIDRIA non-opioid to falls with generate and use
number claims opioids use of cataract Among other prescribed with analytics a armed procedures from the a of of demonstrating efforts, scientists cataract reduces Watson team providing data IBM postoperatively. and in on surgery data technology of that large are quantity OMIDRIA
the Further, Professor Cataract York our in journal Donnenfeld, in "Clinical reduction that use peer-reviewed in as scores. published update, mentioned Ophthalmology" third quarter study recent VAS the pain during Surgery, Eric and and President Dr. and a University Clinical New of Society OMIDRIA of of demonstrating fentanyl resulted Ophthalmology Refractive past both American a at
to underway Another abilities. clinical OMIDRIA's currently opioid-sparing trial is demonstrate
VA volume centers. Part the in growing the published the of Medicare as commercial benefits and System the With patients of on as across of Med OMIDRIA, expand continues data B utilization Advantage and to and well drug academic
of training, program on Top centers X Bascom country, at Eye top one for of number including University in academic now the in XX XX is X and ranked the ophthalmology the the of Institute training formulary the OMIDRIA Miami. Palmer
loss used course, reduced pharmacy are surgeons had lawsuits of a concern against a safety XX compounding to that Of because Dallas, patients. surgery and vision surgeons, and product facilities rates surgeons, in In and a least patients. complications patient the the facility the cataract were caused critical administrators filed surgical compounded at
OMIDRIA to the grave the but that patients, and facilities, Recently, products present of also risk a physicians physical serious not of financial products use large FDA-approved were settled risk number of cases only compounded instead underscoring like its to facilities potential surgeons kind. for In drug, the their surgical payment liability. and relegated is compounded only of separate the FDA-approved significant product less OMIDRIA safe products using are financial of to absence practices. incurring
alternative believe complement activator is to indications premier OMSXXX, complement our OMSXXX, To need the along MASP-X. turn in inhibitors. pathway. others is of antibody component breadth and pathway in let's research understand Now potential franchise. only targeting the and our industry for by the community of major the targeting We look another MASP-X other the alternative key with pursued that indications at drug one OMSXXX
significant a favorable highest hemoglobinuria in These OMSXXX Our expect the complement safety of effects profile more dosing. frequency with of potent include show nocturnal on no or to focus even to track approved is to results inhibition tested. other dose adverse Preliminary on hemolysis remains and next a administration ability more or development. toxicology have convenient initial much providing at quarter. the route clinic lower hemolysis, paroxysmal enter advantages self-administered we where inhibitors while over intravascular of inhibit PNH the extravascular
Beyond narsoplimab is complement progressing management and OMSXXX, franchise nicely. our life-cycle for our strategy of
acting early against by XXXX, second generation longer clinical MASP-X orally followed planned an available antibody is for inhibitor Our against entry MASP-X. molecule small in
inhibitors developing molecule of We MASP-X. small also are
phosphodiesterase to compulsions. Phase Now X tolerated well with drug consistent PK our without X good and let's discuss or was once trial, safety. briefly program last taken PDEX daily our dosing profile treat addictions or Its which was In with with fall, completed food. our
Our focus development X is our and we addiction Phase are nicotine planning program.
of which for activate in GPRXXX We found of is exposing that the interleukin-X like our and on micro interferon-gamma GPRXXX killing update and data protein-coupled effective quarter, environment required link GPRXXX presented phosphatidylserine, tumor functions conferences membranes pipeline with demonstrating is of the on T-cell between highly features release cells. responses. program. tumors. resulting abundant an of and mediated Last T-cells, a Cell anti-tumor discussion suppression of or both our Omeros stimulated close immune Let's G by in suppression GPCR Boston Geneva phosphatidylserine the tumor in at receptor
growth in We the currently tumor the and inhibition We cancer mice of tumor an models models in evaluating have in effective found reconstituted GPRXXX human are of are presence with in that more the co-therapy. mice impact system. immune of GPRXXX colon controlling immune-stimulating at melanoma deficient
Another GPRXXX. AXA GPCRs of adenosine and high AXB resistance is play to cell inhibitors receptors tumors Yervoy. which immune thought in cell adenosine tumor such to Keytruda, These signals a death and role patient product immune in checkpoint in to found Opdivo, significant concentration similar as through are
production We and of have found GPRXXX synergistic complete tumor phosphatidylserine and cell and that in in of presence IL-X and the inhibition results interferon-gamma. both the adenosine restoration receptors the of killers, adenosine, of
the assessing adenosine inhibition currently pathway tumor GPRXXX and of are the We combined animal in models. effects
tumors Omeros the how to strategies system, GPRXXX understanding With and immune novel well the inhibitors cancer clinic. our and bring positioned proprietary transformative immunotherapy of new this suppress to is
over also he our with he's call for financial a an to handing working our an will Kurt of obviously Before welcome Mike that role former context, of I'd to Board really Amazon, Kurt like quarter overview ongoing is strong growth. to our important Treasurer of fourth accomplished look good Kurt results, network and Directors. Zumwalt of we guy, in forward expect and to a financial with play the
Mike?
